Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

Atsunori Kashiwagi1*, Kenichi Kazuta2, Satoshi Yoshida2, Itsuro Nagase2
1Shiga University of Medical Science, Otsu, Shiga, and 2Astellas Pharma Inc., Chuo-ku, Tokyo, Japan

Keywords
Hyperglycemia, Oral antidiabetic drugs, Sodium-dependent glucose co-transporter 2

*Correspondence
Atsunori Kashiwagi
Tel.: +81-77-548-2500
Fax: +81-77-548-2409
E-mail address: kasiwagi@belle.shiga-med.ac.jp

J Diabetes Invest 2014; 5: 382–391
doi: 10.1111/jdi.12156

INTRODUCTION
The worldwide prevalence of diabetes mellitus has been estimated at 285 million in 2010, and is projected to reach 439 million by 20301. A Japanese National Health and Nutrition survey in the year 2007 estimated that 8.9 million people suffer from type 2 diabetes in Japan2. Although oral antihyperglycemic drugs with various mechanisms of action are currently available, 66% of patients still have higher post-treatment glycated hemoglobin (HbA1c) levels than those recommended by the Japan Diabetes Society3, highlighting extant unmet needs for glycemic control.
The kidney plays an important role in maintaining glucose homeostasis in the body. Blood glucose is filtered by the glomerulus, and almost all filtered glucose molecules are reabsorbed in the proximal renal tubule. Nearly 90% of filtered glucose in the kidney is reabsorbed through sodium-dependent glucose cotransporter 2 (SGLT2) in the S1 segment of the renal proximal tubules4,5,6. Therefore, inhibiting SGLT2-mediated glucose reabsorption helps to lower blood glucose concentrations.

Ipragliflozin (ASP1941; Astellas Pharma Inc. Tokyo, Japan and Kotobuki Pharmaceutical Co., Ltd, Nagano, Japan) is a novel and selective SGLT2 inhibitor, and is one of the first published C-aryl glycoside compounds (as opposed to the labile ortho-attachment of O-glycoside molecules seen in in vivo conditions5). Previously reported to lower blood glucose levels in both insulin-deficient and insulin-resistant animal models of diabetes mellitus, the compound is currently under consideration for use in treating patients with diabetes6,8,9. Ipragliflozin is generally safe and well-tolerated after both single and repeated dosing, and shows a dose-dependent increase in urinary glucose excretion in healthy volunteers6,10,11. Similar results were reported by another SGLT2 inhibitor, dapagliflozin, in healthy volunteers12.

Here, we carried out a double-blind, randomized, placebo-controlled study to assess the dose–response relationship for the efficacy and safety of ipragliflozin administered for 12 weeks in Japanese patients with type 2 diabetes mellitus.

MATERIALS AND METHODS

The study was carried out in accordance with the Declaration of Helsinki, Good Clinical Practice and the International Conference on Harmonization guidelines. The study protocol was reviewed and approved by the institutional review board of each institution, and all patients provided written informed consent. All measured HbA1c values, which were originally reported according to the requirements of the Japan Diabetes Society, were converted to the corresponding National Glycohemoglobin Standardization Program (NGSP) values, using the equation established in Japan13.

Study Design

The present multicenter, placebo-controlled, double-blind, parallel-group, dose–response study assessed the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus. The study was carried out between March 2008 and March 2009 at 39 sites in Japan. Patients were randomized to receive either a placebo or once-daily doses of ipragliflozin (12.5, 25, 50 or 100 mg) before breakfast. All patients underwent an initial 4-week screening period, where previously administered antidiabetic drugs were washed out, followed by a 2-week run-in period with a placebo. Patients were then randomized to receive 12 weeks of treatment, and were followed for an additional 1–6 weeks after study drug treatment completion.

Patients

Eligible patients were aged 20–75 years, had been diagnosed with type 2 diabetes for at least 12 weeks, had baseline body mass indices (BMIs) of 20.0–45.0 kg/m2, and had fasting serum C-peptide levels of >0.6 mg/mL. Patients were instructed to continue with their recommended diets and exercise habits. If patients were previously treated with antidiabetes drugs, they underwent a washout period of at least 6 weeks between a 4-week screening period and a 2-week run-in period before the start of the randomized treatment. Use of other medications, except for antidiabetes drugs, was permitted during the study period.

Patients with HbA1c levels of 7.4–10.5%, with variability between measurements of 1.0% or less, were recruited during a screening phase. We excluded patients with advanced diabetes complications, type 1 diabetes, history of clinically significant renal disease, dysuria caused by a neurogenic bladder or benign prostatic hypertrophy, repeated urinary tract infections (UTIs) or a UTI at screening, chronic disease requiring the continuous use of steroids or immunosuppressants, cardiac events within the preceding 24 weeks, uncontrolled severe hypertension (systolic blood pressure >170 mmHg or diastolic blood pressure >95 mmHg), abnormal deviation from normal ranges of serum creatinine (Cr) levels, or macroalbuminuria (albumin/creatinine ratio >300 mg/g Cr in urinalysis). Pregnant or breast-feeding women were also excluded from the study.

Clinical Evaluations

During the treatment period, blood and urine samples were collected at weeks 0, 2, 4, 8, and 12. Follow-up examinations were carried out between 1 and 6 weeks after treatment completion. The primary efficacy outcome was change in HbA1c levels from baseline to the end of treatment. Secondary efficacy variables included fasting plasma glucose (FPG) levels, bodyweight and blood pressure. Safety evaluations included the monitoring of the nature, frequency and severity of adverse events (AEs). Laboratory tests, including routine blood and urine chemistries, were also carried out.

Statistical Analysis

Efficacy and safety analyses were carried out in patients who received at least one dose of the study drug and who underwent at least one post-treatment assessment.

For the primary variable, pair-wise comparisons by analysis of covariance with baseline value as a covariate were carried out between the placebo group and each ipragliflozin group as a primary analysis. To adjust the type I error rate, a hierarchical testing procedure was used at an overall two-sided significance level at 0.05. Additionally, Tukey’s multiple comparison tests were carried out to compare among all treatment groups. Post-hoc subgroup analyses were carried out to compare outcomes between drug-naive patients and patients who had been previously treated with an antidiabetes medication (drug-trea-
RESULTS

Patient Demographics

A total of 361 patients were randomized to either the ipragliflozin or placebo groups, and 360 patients had at least one efficacy variable measured after randomization (Figure 1). A total of 52% of patients were drug-naive, whereas 48% had received antidiabetes medication in the past. Patient demographics and baseline characteristics, including the previous use of antidiabetes medication, were similar across all groups (Table 1). All anti-diabetic medications in drug-treated groups were washed out for at least 6 weeks before randomization. In all treatment groups, the mean compliance rate was ≥97%.
Table 1 | Demographic and baseline characteristics of patients

|                      | Placebo (n = 69) | Ipragliflozin 12.5 mg (n = 73) | 25 mg (n = 74) | 50 mg (n = 72) | 100 mg (n = 72) |
|----------------------|------------------|-------------------------------|----------------|----------------|----------------|
| Sex, n (male/female) | 49/20            | 43/30                         | 49/25          | 43/29          | 49/23          |
| Age (years)          | 55.2 ± 9.7       | 55.3 ± 10.2                   | 57.0 ± 10.4    | 55.9 ± 11.4    | 56.0 ± 10.4    |
| Duration of diabetes (months) | 75.7 ± 66.5 | 758 ± 62.2                     | 76.9 ± 59.7    | 79.7 ± 81.3    | 93.6 ± 87.9    |
| Previous medication for diabetes, n (%) | | | | | |
| Drug-naïve           | 39 (56.5)        | 32 (43.8)                     | 40 (54.1)      | 43 (59.7)      | 34 (47.2)      |
| Drug-treated†        | 30 (43.5)        | 41 (56.2)                     | 34 (45.9)      | 29 (40.3)      | 38 (52.8)      |
| Sulfonylurea         | 20 (29.0)        | 21 (28.8)                     | 17 (23.0)      | 14 (19.4)      | 15 (20.8)      |
| Metformin            | 4 (5.8)          | 12 (16.4)                     | 8 (10.8)       | 7 (9.7)        | 7 (9.7)        |
| Alpha-glucosidase inhibitor | 8 (11.6) | 6 (8.2)                      | 8 (10.8)       | 8 (11.1)       | 9 (12.5)      |
| Glinide              | 1 (1.4)          | 4 (5.5)                      | 3 (4.1)        | 2 (2.8)        | 4 (5.6)        |
| Thiazolidinedione    | 7 (10.1)         | 7 (9.6)                      | 9 (12.2)       | 10 (13.9)      | 5 (6.9)        |
| BMI (kg/m²)          | 25.1 ± 3.4       | 25.6 ± 3.5                    | 26.2 ± 4.0     | 25.8 ± 3.5     | 25.9 ± 3.8     |
| Bodyweight (kg)      | 666 ± 106        | 674 ± 128                     | 690 ± 145      | 678 ± 119      | 683 ± 124      |
| HbA1c (%)            | 8.36 ± 0.79      | 8.39 ± 0.90                   | 8.32 ± 0.83    | 8.33 ± 0.80    | 8.25 ± 0.76    |
| Fasting plasma glucose (mg/dL) | 186.4 ± 39.5  | 185.4 ± 40.0                  | 1780 ± 38.8    | 1734 ± 349     | 1775 ± 321     |
| Systolic blood pressure (mmHg) | 126.5 ± 12.7  | 128.3 ± 13.6$\pm$ | 127.7 ± 13.6    | 1275 ± 14.3     | 1261 ± 12.7     |
| Diastolic blood pressure (mmHg) | 77.8 ± 105      | 77.2 ± 9.1$\pm$   | 77.1 ± 9.9     | 779 ± 11.1     | 765 ± 9.2     |

Each value represents the mean ± standard deviation, unless stated otherwise. †All patients who received at least one dose of study drug and had at least one efficacy variable measured after the start of treatment (n = 360). ‡Drug-treated patients could be on more than one oral antidiabetes medication before screening. §n = 74; one patient did not have efficacy data, but did have blood pressure data and safety data. BMI, body mass index; HbA1c, glycated hemoglobin.

Glycemic Control Using Ipragliflozin

At the end of the treatment period, mean HbA1c levels in the 12.5, 25, 50, and 100 mg ipragliflozin groups were dose-dependently decreased by 0.11%, 0.47%, 0.79%, and 0.81% from baseline value, respectively (Table 2). Because of an increase in HbA1c levels of 0.50% above the basal value in the placebo group, the adjusted mean difference in HbA1c change from baseline to the end of treatment between the placebo and 12.5, 25, 50, and 100 mg ipragliflozin groups were −0.61%, −0.97%, −1.29%, and −1.31%, respectively (Table 2). HbA1c levels decreased significantly in the ipragliflozin groups at all tested doses compared with the placebo (P < 0.001). Using the Tukey’s multiple comparison tests, the differences between all treatment groups were statistically significant except between 25 and 50 mg, and between 50 and 100 mg (Table 2). The maximum effect was obtained at a dose of 50 mg.

As the wash-out period was 6 weeks, the analysis was additionally carried out excluding the patients washed out of thiazolidinediones. The results showed an increase in HbA1c levels of 0.37% above the basal value in the placebo group, the adjusted mean difference in HbA1c change from baseline to the end of treatment between the placebo and 12.5, 25, 50, and 100 mg ipragliflozin groups were −0.55%, −0.89%, −1.20%, and −1.18%, respectively.

At the end of treatment, HbA1c levels <7.0% were achieved in 4.1%, 8.1%, 21.1%, and 23.6% of patients in the 12.5, 25, 50, and 100 mg ipragliflozin groups, respectively, compared with 2.9% of patients in the placebo group. Subgroup analyses on differences in drug effects were carried out by the drug-naïve and drug-treated patients, obese (BMI ≥25 kg/m²) and non-obese (BMI <25 kg/m²) patients, and patients with baseline HbA1c levels <8.4% and ≥8.4% (Figure 2). After the treatment with ipragliflozin, HbA1c levels significantly decreased at all tested doses except the 12.5 mg group in obese patients, compared with the placebo. The interactions between the treatment group and these subgroup factors for the change in HbA1c were assessed using analysis of variance to detect differential patterns. Interactions between the treatment group and drug naïve/non-naïve, and obese/non-obese patients were not significant (P = 0.106 and P = 0.228, respectively). However, the interaction between the treatment group and baseline HbA1c levels <8.4% and ≥8.4% was significant (P < 0.001).

Fasting Plasma Glucose

In response to ipragliflozin administration, FPG levels decreased dose-dependently over the 12-week treatment period. In all four ipragliflozin groups, mean FPG levels decreased from the start of treatment, and remained almost constantly in the lowest levels from week 2 until week 12 in both the 50 and 100 mg ipragliflozin groups (Table 2). Adjusted mean changes in FPG from baseline to the end of treatment were −12.0 mg/dL in the placebo group, and −15.6, −23.7, −34.1, and −46.9 mg/dL in the 12.5, 25, 50, and 100 mg ipragliflozin groups, respectively (P < 0.001 for all ipragliflozin groups vs placebo). The differ-
Table 2 | Dose dependent reduction of glycated hemoglobin concentrations and fasting plasma glucose levels by Ipragliflozin treatment

|                  | Placebo (n = 69) | 12.5 mg (n = 73) | 25 mg (n = 74) | 50 mg (n = 72) | 100 mg (n = 72) |
|------------------|-----------------|-----------------|----------------|---------------|----------------|
| HbA1c (%)       |                 |                 |                |               |                |
| Week 0†         | 8.36 ± 0.79     | 8.39 ± 0.90     | 8.32 ± 0.83    | 8.33 ± 0.80   | 8.25 ± 0.76    |
| Week 4†         | 8.58 ± 1.10     | 8.34 ± 1.05     | 8.05 ± 0.86*   | 7.93 ± 0.78*  | 7.85 ± 0.73*   |
| Week 8†         | 8.62 ± 1.24*    | 8.23 ± 1.15     | 7.81 ± 0.76*   | 7.57 ± 0.71*  | 7.57 ± 0.72*   |
| Week 12†        | 8.62 ± 1.19*    | 8.10 ± 0.91*    | 7.78 ± 0.75*   | 7.49 ± 0.70*  | 7.40 ± 0.68*   |
| Change from baseline | 0.50 ± 0.090    | −0.11 ± 0.09    | −0.47 ± 0.09   | −0.79 ± 0.09  | −0.81 ± 0.09   |
| Difference vs placebo | −0.61 [−0.85, −0.36] | −0.97 [−1.21, −0.72] | −1.29 [−1.54, −1.04] | −1.31 [−1.55, −1.06] |
| P-value          | <0.001          | <0.001          | <0.001         | <0.001        |                |
| P-value comparison between each dose groups | P < 0.05 (vs 12.5 mg) | P < 0.001 (vs 12.5 mg) | P < 0.001 (vs 12.5 mg) | P < 0.05 (vs 25 mg) |
| FPG (mg/dL)     |                 |                 |                |               |                |
| Week 0†         | 186.4 ± 39.5    | 185.4 ± 40.0    | 178.0 ± 38.8   | 173.4 ± 34.9  | 177.5 ± 32.1   |
| Week 2†         | 184.3 ± 39.9    | 172.8 ± 37.2*   | 159.8 ± 34.2*  | 142.6 ± 24.3* | 141.4 ± 18.8*  |
| Week 4†         | 189.8 ± 43.3    | 166.4 ± 34.7*   | 151.4 ± 28.0*  | 144.1 ± 29.1* | 136.5 ± 20.3*  |
| Week 8†         | 190.3 ± 42.9*   | 168.1 ± 32.8*   | 153.3 ± 29.9*  | 137.9 ± 19.6* | 135.6 ± 19.6*  |
| Week 12†        | 189.7 ± 36.7*   | 163.0 ± 30.7*   | 151.7 ± 31.9*  | 140.1 ± 24.1* | 130.6 ± 17.6*  |
| Change from baseline at EOT† | 120.0 ± 3.0    | −15.6 ± 3.0     | −23.7 ± 3.0    | −34.0 ± 3.1   | −46.9 ± 3.1    |
| Difference vs placebo | −27.6 [−36.0, −19.2] | −35.7 [−44.1, −27.3] | −46.0 [−54.5, −37.6] | −58.9 [−67.4, −50.4] |
| P-value          | <0.001          | <0.001          | <0.001         | <0.001        |                |
| P-value comparison between each dose groups | P < 0.001 (vs 12.5 mg) | P < 0.001 (vs 12.5 mg) | P < 0.05 (vs 25 mg) | P < 0.05 (vs 50 mg) |

Each value represents †The mean ± standard deviation, ‡The adjusted mean ± standard error, *P < 0.05 (compared with baseline by t-test). CI, confidence interval; EOT, end of treatment; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin.

ences between all treatment groups were statistically significant except between 12.5 and 25 mg, and between 25 and 50 mg by analysis of covariance.

**Bodyweight and Blood Pressure**

Adjusted mean changes in bodyweight from baseline at the end of treatment were −0.39 kg for patients receiving the placebo, and −1.46, −1.69, −1.81, and −2.10 kg in the 12.5, 25, 50, and 100 mg ipragliflozin groups, respectively (Figure 3a; P < 0.001 for all ipragliflozin groups vs placebo). After termination of ipragliflozin treatment, bodyweight was regained during the follow-up period, but the reduction was still significantly below the baseline values. Although the effects of ipragliflozin on bodyweight were variable, the reduction in bodyweight was found in both drug-treated and drug-naive patients by the subgroup analyses (Figure 3b). The mean change in bodyweight from baseline values to the end of the treatment in drug-naive patients was +0.06 kg in the placebo group and −1.70 kg in the 100 mg ipragliflozin group. In addition, reduction in bodyweight with ipragliflozin was observed in both obese (BMI ≥25 kg/m²) and non-obese (BMI <25 kg/m²) patients.

The changes in systolic blood pressure from baseline to the end of treatment tended to decrease in the ipragliflozin-treated groups compared with the placebo group. However, these differences were not significant (data not shown).

**Safety and Laboratory Values**

Adverse events occurred at similar frequencies across the placebo and ipragliflozin-treated groups. AEs and drug-related AEs were not dose-dependent (P = 0.451 and P = 0.417, respectively). Rates of discontinuation because of drug-related AEs were low at 0–3% across the treatment groups. Serious AEs occurred in four patients: three patients (4.3%) in the placebo group and one patient (1.4%) in the ipragliflozin 12.5 mg group. No cases of cancer and no deaths were reported in this small scale and short duration study using ipragliflozin. A single mild symptomatic hypoglycemic event occurred in a patient in the 100 mg ipragliflozin group, which was not confirmed by
| Subgroup                  | Treatment       | n  | Baseline | Change from baseline at the end of treatment (mean±SE) | Difference vs PLA (95% CI) | P-value vs Placebo |
|--------------------------|-----------------|----|----------|-------------------------------------------------------|---------------------------|------------------|
| Drug-naïve               | Placebo         | 39 | 8.27     | -0.14 ± 0.09                                         | -0.61 [−0.89, −0.34]       | P < 0.001        |
|                          | Ipragliflozin   |    |          |                                                       |                           |                  |
|                          | 12.5 mg         | 32 | 8.27     | -0.47 ± 0.10                                         | -0.61 [−0.89, −0.34]       | P < 0.001        |
|                          | 25 mg           | 40 | 8.21     | -0.62 ± 0.09                                         | -0.76 [−1.02, −0.50]       | P < 0.001        |
|                          | 50 mg           | 42 | 8.37     | -0.89 ± 0.09                                         | -1.03 [−1.29, −0.78]       | P < 0.001        |
|                          | 100 mg          | 34 | 8.11     | -1.04 ± 0.10                                         | -1.18 [−1.45, −0.91]       | P < 0.001        |
| Drug-treated             | Placebo         | 30 | 8.48     | 0.96 ± 0.14                                          | -0.80 [−1.17, −0.43]       | P < 0.001        |
|                          | Ipragliflozin   |    |          |                                                       |                           |                  |
|                          | 12.5 mg         | 41 | 8.48     | 0.16 ± 0.12                                          | -0.89 [−1.25, −0.53]       | P < 0.001        |
|                          | 25 mg           | 34 | 8.46     | -0.30 ± 0.14                                         | -1.26 [−1.65, −0.87]       | P < 0.001        |
|                          | 50 mg           | 29 | 8.28     | -0.60 ± 0.15                                         | -1.56 [−1.97, −1.16]       | P < 0.001        |
|                          | 100 mg          | 38 | 8.37     | -0.62 ± 0.13                                         | -1.58 [−1.96, −1.20]       | P < 0.001        |
| BMI ≥25 kg/m²            | Placebo         | 31 | 8.37     |                                                       |                           |                  |
|                          | Ipragliflozin   |    |          |                                                       |                           |                  |
|                          | 12.5 mg         | 35 | 8.49     | 0.06 ± 0.13                                          | -0.35 [−0.73, 0.02]        | P = 0.065        |
|                          | 25 mg           | 45 | 8.40     | -0.48 ± 0.12                                         | -0.89 [−1.25, −0.53]       | P < 0.001        |
|                          | 50 mg           | 38 | 8.50     | -0.89 ± 0.13                                         | -1.30 [−1.67, −0.93]       | P < 0.001        |
|                          | 100 mg          | 40 | 8.25     | -0.83 ± 0.12                                         | -1.24 [−1.61, −0.88]       | P < 0.001        |
| BMI <25 kg/m²            | Placebo         | 38 | 8.36     |                                                       |                           |                  |
|                          | Ipragliflozin   |    |          |                                                       |                           |                  |
|                          | 12.5 mg         | 38 | 8.30     | -0.27 ± 0.11                                         | -0.84 [−1.16, −0.52]       | P < 0.001        |
|                          | 25 mg           | 29 | 8.21     | -0.47 ± 0.13                                         | -1.04 [−1.39, −0.70]       | P < 0.001        |
|                          | 50 mg           | 33 | 8.14     | -0.69 ± 0.12                                         | -1.27 [−1.60, −0.94]       | P < 0.001        |
|                          | 100 mg          | 32 | 8.24     | -0.78 ± 0.13                                         | -1.35 [−1.69, −1.02]       | P < 0.001        |
| Baseline                 | Placebo         | 28 | 9.15     |                                                       |                           |                  |
| HbA1c levels ≥8.4%       | Ipragliflozin   |    |          |                                                       |                           |                  |
|                          | 12.5 mg         | 28 | 9.31     | -0.17 ± 0.17                                         | -1.02 [−1.50, −0.53]       | P < 0.001        |
|                          | 25 mg           | 30 | 9.16     | -0.88 ± 0.17                                         | -1.72 [−2.20, −1.25]       | P < 0.001        |
|                          | 50 mg           | 25 | 9.22     | -1.13 ± 0.18                                         | -1.98 [−2.48, −1.48]       | P < 0.001        |
|                          | 100 mg          | 27 | 9.06     | -1.23 ± 0.18                                         | -2.08 [−2.57, −1.59]       | P < 0.001        |
| Baseline                 | Placebo         | 41 | 7.83     |                                                       |                           |                  |
| HbA1c levels <8.4%       | Ipragliflozin   |    |          |                                                       |                           |                  |
|                          | 12.5 mg         | 45 | 7.81     | -0.07 ± 0.08                                         | -0.31 [−0.54, −0.08]       | P = 0.009        |
|                          | 25 mg           | 44 | 7.75     | -0.19 ± 0.08                                         | -0.43 [−0.66, −0.20]       | P < 0.001        |
|                          | 50 mg           | 46 | 7.86     | -0.61 ± 0.08                                         | -0.84 [−1.07, −0.62]       | P < 0.001        |
|                          | 100 mg          | 45 | 7.76     | -0.55 ± 0.08                                         | -0.79 [−1.02, −0.56]       | P < 0.001        |

Figure 2 | Subgroup analyses by treatment experience, body mass index (BMI) level and baseline glycated hemoglobin (HbA1c) levels. Effects did not differ between drug-naïve and drug-treated patients, or between patients with BMI of ≥25 kg/m² and BMI <25 kg/m² (P = 0.106 and P = 0.228, respectively). Reductions in HbA1c values were greater in patients with HbA1c levels ≥8.4% than in those with HbA1c levels <8.4% (P < 0.001). CI, confidence interval; PLA, placebo; SE, standard error.

plasma glucose measurement. Pollakiuria and polyuria occurred in two patients (2.9%) in the placebo group, and in two (2.7%), five (6.8%), six (8.3%), and six (6.8%) patients in the 12.5, 25, 50, and 100 mg ipragliflozin groups, respectively. UTIs were observed in one patient in the placebo group, three patients in the 50 mg ipragliflozin group and one patient in the 100 mg ipragliflozin group. All cases of UTIs involved mild cystitis, were found in female patients and were resolved by antibiotic treatment. Mild vaginal candidiasis in one patient in each of the 12.5 mg and 50 mg ipragliflozin groups improved sufficiently with oxiconazole nitrate treatment. The patient with vaginal candidiasis in the 50 mg ipragliflozin group also had bacterial vaginitis. Genital pruritus occurred in one patient in each of the 12.5, 50 and 100 mg ipragliflozin groups.

In the ipragliflozin-treated groups, hematocrit was mildly increased by 1.5–2.0% at every dose. Similarly, blood urea nitrogen (BUN) and urinary osmolality were also mildly increased compared with placebo. Conversely, alanine amino transferase (ALT) levels were significantly decreased at the 25, 50 and 100 mg dose. Furthermore, serum phosphorus and
magnesium concentrations, and urinary excretion of magnesium also increased, and urinary pH slightly decreased \((P < 0.001; \text{Table 3})\).

**DISCUSSION**

The present study found that HbA1c levels significantly decreased by more than 1% compared with the placebo after 12 weeks of treatment with once daily 50 or 100 mg doses of ipragliflozin. These results might be clinically meaningful if the levels could be maintained long term, as it has been reported that a reduction of HbA1c by 1% has been associated with a 21% reduction in the relative risk of death, 37% reduction in risk of microvascular complications and 14% reduction in risk of myocardial infarction\(^{(12)}\) in patients with type 2 diabetes mellitus.

In the present study, the 6-week washout period might be insufficient to stabilize the pretreatment HbA1c levels, as HbA1c levels in the placebo group showed a 0.5% increase above basal levels during the follow-up period. However, the change in HbA1c levels from baseline to the end of treatment dose-dependently decreased by a maximum of 1.29% below placebo levels in the 50 mg ipragliflozin group and 1.31% below placebo levels in the 100 mg ipragliflozin dose group. The evidence is further supported by the results showing a similar reduction in HbA1c levels at 50 and 100 mg ipragliflozin doses (by 1.03% and 1.18%, respectively) in drug-naive patients, whereas HbA1c levels in the placebo group showed a 0.14% increase between baseline and the end of treatment. In addition, the effect of thiazolidinediones might remain for at least 2 or...
3 months after discontinuing the treatment. In order to confirm its effect, further analysis was carried out excluding the patient treated with thiazolidinediones; however, HbA1c, FPG and bodyweight showed almost the same results as in the previous analysis (data not shown).

Furthermore, ipragliflozin treatment also resulted in similar HbA1c reductions among the obese and non-obese Japanese patients. Although other SGLT2 inhibitors also reduce glycemic parameters in patients with type 2 diabetes, these are the first data showing equal efficacy in both obese and non-obese Japanese type 2 diabetes patients.

More patients receiving ipragliflozin monotherapy achieved an HbA1c level <7.0% (21.1% of the 50 mg group and 23.6% of the 100 mg group) than did with the placebo (29.0%). Ipragliflozin was also associated with a significant reduction in FPG levels. Interestingly, the reduction was found at 2 weeks after the start of treatment, and was maintained until the end of treatment in both the 50 and 100 mg groups.

Several classes of oral antidiabetes medications cause weight gain. In the present study, ipragliflozin induced significant dose-dependent reductions in bodyweight compared with the placebo, likely caused by ipragliflozin-induced dose-dependent increases in glucosuria, as recent phase 1 and phase 2 studies have shown that ipragliflozin administration leads to increased excretion of urinary glucose, resulting in energy loss that might contribute to reductions in bodyweight. Furthermore, ipragliflozin might also exert a mild osmotic diuretic effect, reflected by the mild increases in hematocrit and BUN levels, which could contribute to the weight reduction and explain the rapid partial regain of weight after discontinuation of the drug.

Hypertension is a risk factor for cardiovascular complications in type 2 diabetes patients, and drugs including a low dose of diuretics are often effective in reducing blood pressure, because they mitigate the volume overload seen in these patients. A mild reduction in systolic blood pressure was observed with the ipragliflozin treatment, which is consistent with the results reported for dapagliflozin. The clinical meaning of these mild effects of ipragliflozin on bodyweight and blood pressure will be further evaluated in ongoing clinical trials. The clinical significance of mild changes in electrolytes, such as serum phosphorus and magnesium concentrations, remains unclear in the present study.

Although ipragliflozin was generally safe and well tolerated in the present study, pollakiuria tended to occur more frequently in ipragliflozin-treated groups than in the placebo group. UTIs and genital infections are prevalent in women with diabetes mellitus, and increased incidences of both conditions have been reported in placebo-controlled studies using another SGLT2 inhibitor, dapagliflozin. However, in the present study, both UTIs and genital infections were similarly prevalent between the placebo and ipragliflozin groups. Long-term and large-scale studies of ipragliflozin are required to further assess the frequency and clinical significance of these AEs. However, the present data support the safety of ipragliflozin reported in other studies, and show that SGLT2 inhibitors have a favorable safety profile.

Although the relationship between antidiabetes drugs and cancer risk has been a concern in recent years, no cancer events were reported in our study of ipragliflozin. Much larger patient groups and extended exposure time are likely required to determine whether or not treatment with ipragliflozin presents a similar cancer risk.

In summary, ipragliflozin efficiently improved glycemic control and bodyweight in a dose-dependent manner on adminis-

---

**Table 3 | Mean changes in laboratory values from baseline to the end of ipragliflozin treatment**

|                          | Placebo | Ipragliflozin |
|--------------------------|---------|---------------|
|                          | 12.5 mg | 25 mg         | 50 mg         | 100 mg         |
| Hematocrit (%)           | −0.08 ± 2.61 | 1.47 ± 1.95** | 1.49 ± 2.09** | 1.98 ± 2.09** | 1.98 ± 1.90** |
| AST (IU/L)                | 1.6 ± 12.8 | −0.6 ± 6.3    | −1.3 ± 11.1   | −1.1 ± 5.2     | −1.8 ± 11.0    |
| ALT (IU/L)               | 0.0 ± 7.3 | −1.9 ± 8.5    | −5.2 ± 11.3*  | −3.9 ± 9.8*    | −5.8 ± 10.8** |
| BUN (mg/dL)              | −0.3 ± 3.5 | 1.3 ± 28*     | 1.0 ± 3.3*    | 2.2 ± 3.3**    | 1.8 ± 3.5**    |
| sCr (mg/dL)              | −0.02 ± 0.07 | −0.01 ± 0.06 | −0.01 ± 0.05* | 0.00 ± 0.05*   | 0.01 ± 0.06*   |
| Uric acid (mg/dL)        | −0.04 ± 0.64 | −0.05 ± 0.63 | −0.39 ± 0.73  | −0.30 ± 0.87   | −0.13 ± 0.76   |
| uOsm (mOsm/L)            | −4 ± 303 | 123 ± 269     | 51 ± 250      | 146 ± 242*     | 165 ± 273**    |
| Urinary pH               | 0.04 ± 0.67 | −0.23 ± 0.67  | −0.34 ± 0.58** | −0.32 ± 0.55** | −0.39 ± 0.65** |
| Serum electrolytes       |         |               |               |                |
| P (mg/dL)                | −0.03 ± 0.37 | 0.05 ± 0.32   | 0.10 ± 0.39*  | 0.13 ± 0.39*   | 0.18 ± 0.41*   |
| Mg (mg/dL)               | −0.03 ± 0.14 | 0.04 ± 0.13*  | 0.08 ± 0.13** | 0.09 ± 0.13**  | 0.12 ± 0.13**  |
| Urinary electrolytes     |         |               |               |                |
| Mg (mg/g Cr)             | 1.4 ± 27.4 | 13.5 ± 240*   | 14.9 ± 279*   | 12.9 ± 207*    | 11.9 ± 304*    |

Each value represents the mean ± standard deviation. *P < 0.05 and **P < 0.001 (compared with placebo by t-test). ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; Mg, magnesium; P, phosphorus; sCr, serum creatinine; uOsm, urinary osmolarity.
tation to Japanese patients with type 2 diabetes mellitus. Notably, decreases in HbA1c levels were similar between obese and non-obese patients. Ipragliflozin at once-daily doses up to 100 mg for 12 weeks appears to be safe, as no clinically significant AEs were observed. Given this ostensibly favorable safety profile, the potential therapeutic benefits of ipragliflozin on reductions in bodyweight and blood pressure warrant further investigation in Japanese patients with type 2 diabetes.

ACKNOWLEDGMENTS
Ipragliflozin (ASP1941) is under development by Astellas Pharma Inc. and Kotobuki Pharmaceutical Co., Ltd. This study was funded by Astellas Pharma. A Kashiwagi is a consultant for Astellas and has received consulting fees/honoraria. K Kazuta, S Yoshida and I Nagase are employees of Astellas Pharma Inc., Tokyo, Japan. Primary investigators in 39 Japanese clinical trials are listed in appendix S1. The authors thank Grace Tjon PhD, who provided writing/editorial assistance for this work, which was supported by Astellas.

REFERENCES
1. Shaw JE, et al. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4–14.
2. Ministry of Health, Labour and Welfare. 2007. National Health and Nutrition Survey. http://www.mhlw.go.jp/houdou/2008/12/h1225-5a.html (Japanese).
3. Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan—A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006; 73: 198–204.
4. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280: F10–F18.
5. Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397–404.
6. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377–385.
7. Washburn WN. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat 2009; 19: 1485–1499.
8. Tahara A, Kurosaki E, Yokono M, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 423–436.
9. Tahara A, Kurosaki E, Yokono M, et al. Antidiabetic effects of SGLT2-selective inhibitor Ipragliflozin in streptozotocin–nicotinamide-induced mildly diabetic mice. J Pharmacol Sci 2012; 120: 36–44.
10. Veltkamp SA, Kadokura T, Krauwinkel WJ, et al. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent Glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Invest 2011; 31: 839–851.
11. Kadokura T, Saito M, Utsuno A, et al. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int 2011; 2: 172–182.
12. Komoroski B, Yachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520–526.
13. Atsunori K, Masato K, Eiichi A, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan diabetes society to national glycatedhemoglobin standardization program values. J Diabetes Invest 2012; 3: 39–49.
14. Matsuwaza Y, Inoue S, Ikeda Y, et al. The new diagnostic criteria of obesity. J Japan Soc for Study Obesity 2000; 6: 18–28 (Japanese).
15. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–412.
16. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650–657.
17. Wilding JP, Norwood P, Tjoen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656–1662.
18. Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2013; 15: 432–440.
19. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care 2009; 32: 193–203.
20. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010; 122: 71–80.
21. Schwartz SL, Akinlade B, Klasen S, et al. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011; 13: 1219–1227.
22. Liu J, Lee TW, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in human? Diabetes 2012; 61: 2199–2204.
23. American Diabetes Association. Executive summary: standards of medical care in diabetes–2012. *Diabetes Care* 2012; 35(Suppl. 1): S4–S10.

24. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care* 2010; 33: 2217–2224.

25. Sobel JD. Candidal vulvovaginitis. *Clin Obstet Gynecol* 1993; 36: 153–165.

26. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. *Clin Pharmacol Ther* 2009; 85: 513–519.

**SUPPORTING INFORMATION**

Additional Supporting Information may be found in the online version of this article:

*Appendix S1 | Primary investigators list.*